HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
BMRN
Biomarin Pharmaceutical Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $10.22B
Market Cap
$10.22B
Enterprise Val
$9.25B
P/E Ratio
29.28
P/B Ratio
1.68
Trailing PEG (1Y)
-0.21
As Of
Apr 23, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$6.09B
Gross Margin68.47%
Profit Margin68.47%
Return on Equity5.82%
Return on Assets4.68%
Current Ratio5.21
Debt/Equity0.10
LT Debt/Equity0.10
Revenue Per Share4.55

Income Statement

Dec 31, 2025
Revenue$874.6M
Cost of Revenue$275.7M
Gross Profit$598.9M
R&D$192.4M
SG&A$446.2M
Operating Expenses$643.5M
Operating Income-$44.6M
Interest Expense$2.8M
Tax Expense$19.4M
Net Income-$46.6M
EPS (Basic)$-0.24
EPS (Diluted)$-0.24
EBIT-$24.4M
EBITDA-$3.9M
Consolidated Income-$46.6M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$1.31B
Accounts Receivable$908.2M
Inventory$1.30B
Current Assets$3.95B
LT Investments$492.2M
Property, Plant & Equipment$952.5M
Intangibles$410.0M
Non-Current Assets$3.64B
Total Assets$7.59B
Accounts Payable$759.0M
Current Debt$0.00
Current Liabilities$759.0M
LT Debt$597.2M
Non-Current Liabilities$748.0M
Total Liabilities$1.51B
Total Debt$597.2M
Retained Earnings$154.2M
Shareholder Equity$6.09B
Shares Outstanding192,114,344

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow$99.6M
Investing Cash Flow-$42.4M
Financing Cash Flow$3.2M
CapEx-$40.7M
Free Cash Flow$58.9M
Depreciation & Amort.$20.4M
Stock-Based Comp$46.9M
Acquisitions / Disposals$0.00
Investment Activity$641.0K
Debt Issued/Repaid$0.00
Equity Issued/Repaid$6.7M
Dividends Paid$0.00
Net Change in Cash$61.6M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h